Search and Browse
Download
Enter Data
| Reaction Details | |||
|---|---|---|---|
 | Report a problem with these data | ||
| Target | Serine/threonine-protein kinase B-raf | ||
| Ligand | BDBM50330914 | ||
| Substrate/Competitor | n/a | ||
| Meas. Tech. | ChEMBL_685663 (CHEMBL1285565) | ||
| IC50 | 1±n/a nM | ||
| Citation |  Wang, X; Berger, DM; Salaski, EJ; Torres, N; Dutia, M; Hanna, C; Hu, Y; Levin, JI; Powell, D; Wojciechowicz, D; Collins, K; Frommer, E; Lucas, J Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity. J Med Chem53:7874-8 (2010) [PubMed] Article | ||
| More Info.: | Get all data from this article, Assay Method | ||
| Serine/threonine-protein kinase B-raf | |||
| Name: | Serine/threonine-protein kinase B-raf | ||
| Synonyms: | B-RAF | B-Raf Protein Kinase | B-Raf proto-oncogene serine/threonine-protein kinase | BRAF | BRAF1 | BRAF_HUMAN | RAFB1 | p94 | v-Raf murine sarcoma viral oncogene homolog B1 | ||
| Type: | Serine/threonine-protein kinase | ||
| Mol. Mass.: | 84446.00 | ||
| Organism: | Homo sapiens (Human) | ||
| Description: | P15056 | ||
| Residue: | 766 | ||
| Sequence: |
| ||
| BDBM50330914 | |||
| n/a | |||
| Name | BDBM50330914 | ||
| Synonyms: | 3-(1H-indazol-4-yl)-7-(4-((1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)naphthalen-1-yl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine | CHEMBL1276176 | ||
| Type | Small organic molecule | ||
| Emp. Form. | C34H28N8 | ||
| Mol. Mass. | 548.6397 | ||
| SMILES | CN1C[C@@H]2C[C@H]1CN2c1ccc(-c2ccnc3c(c(nn23)-c2ccncc2)-c2cccc3[nH]ncc23)c2ccccc12 |r,wU:3.3,5.4,(15.66,4.33,;15.67,2.79,;14.34,2,;14.34,.46,;15.43,1.56,;17.01,2.02,;17.01,.48,;15.68,-.3,;15.69,-1.83,;17.03,-2.6,;17.03,-4.14,;15.69,-4.91,;15.7,-6.45,;14.37,-7.22,;14.38,-8.76,;15.71,-9.54,;17.04,-8.76,;18.52,-9.24,;19.43,-7.99,;18.52,-6.73,;17.04,-7.21,;20.97,-7.98,;21.74,-9.32,;23.28,-9.32,;24.05,-7.98,;23.27,-6.65,;21.73,-6.65,;18.99,-10.7,;20.5,-11.02,;20.98,-12.48,;19.94,-13.64,;18.43,-13.32,;17.19,-14.21,;15.95,-13.3,;16.43,-11.85,;17.97,-11.85,;14.37,-4.15,;13.06,-4.93,;11.72,-4.19,;11.69,-2.65,;13.01,-1.87,;14.35,-2.61,)| | ||
| Structure | 
| ||